Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sang Gyun | - |
dc.contributor.author | Kim, Nayoung | - |
dc.contributor.author | Shin, Sung Kwan | - |
dc.contributor.author | Sung, In Kyung | - |
dc.contributor.author | Hong, Su Jin | - |
dc.contributor.author | Park, Hyo-Jin | - |
dc.date.accessioned | 2021-08-11T15:24:22Z | - |
dc.date.available | 2021-08-11T15:24:22Z | - |
dc.date.issued | 2017-03 | - |
dc.identifier.issn | 2234-2400 | - |
dc.identifier.issn | 2234-2443 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/7769 | - |
dc.description.abstract | Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p> 0.05). The frequency of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer due to long-term use of aspirin might be prevented with concomitant use of Albis. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한소화기내시경학회 | - |
dc.title | Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5946/ce.2016.031 | - |
dc.identifier.scopusid | 2-s2.0-85017220828 | - |
dc.identifier.wosid | 000407291600013 | - |
dc.identifier.bibliographicCitation | Clinical Endoscopy, v.50, no.2, pp 179 - 184 | - |
dc.citation.title | Clinical Endoscopy | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 179 | - |
dc.citation.endPage | 184 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002211124 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | GASTRODUODENAL ULCERS | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | ESOMEPRAZOLE | - |
dc.subject.keywordPlus | FAMOTIDINE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Peptic ulcer | - |
dc.subject.keywordAuthor | Aspirin | - |
dc.subject.keywordAuthor | Albis | - |
dc.subject.keywordAuthor | Modified Lanza score | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.